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Cobimetinib and trametinib inhibit platelet MEK but do not cause platelet
dysfunction
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& Jonathan M. Gibbins1
1Institute for Cardiovascular and Metabolic Research, University of Reading, School of Biological Sciences, Reading, UK and 2Department of
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Abstract
The MEK inhibitors cobimetinib and trametinib are used in combination with BRAF inhibitors to
treat metastatic melanoma but increase rates of hemorrhage relative to BRAF inhibitors alone.
Platelets express several members of the MAPK signalling cascade including MEK1 and MEK2
and ERK1 and ERK2 but their role in platelet function and haemostasis is ambiguous as
previous reports have been contradictory. It is therefore unclear if MEK inhibitors might be
causing platelet dysfunction and contributing to increased hemorrhage. In the present study
we performed pharmacological characterisation of cobimetinib and trametinib in vitro to
investigate potential for MEK inhibitors to cause platelet dysfunction.
We report that whilst both cobimetinib and trametinib are potent inhibitors of platelet MEK
activity, treatment with trametinib did not alter platelet function. Treatment with cobimetinib
results in inhibition of platelet aggregation, integrin activation, alpha-granule secretion and
adhesion but only at suprapharmacological concentrations. We identified that the inhibitory
effects of high concentrations of cobimetinib are associated with off-target inhibition on Akt
and PKC. Neither inhibitor caused any alteration in thrombus formation on collagen under flow
conditions in vitro.
Our findings demonstrate that platelets are able to function normally when MEK activity is fully
inhibited, indicating MEK activity is dispensable for normal platelet function. We conclude that
the MEK inhibitors cobimetinib and trametinib do not induce platelet dysfunction and are
therefore unlikely to contribute to increased incidence of bleeding reported during MEK
inhibitor therapy.
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Introduction
Protein kinases mediate many critical signalling events in platelet
activation and enable them to fulfil their role in primary haemos-
tasis. Although platelet kinases have not yet been successfully
targeted for antiplatelet therapy, many kinase inhibitors are now
being used to treat other diseases, including cancers. Some cancer
therapies target kinases that are also present in the platelet and
can cause platelet dysfunction and increase risk of bleeding
events. Dasatinib (Src), ibrutinib (Btk) and imatinib (Bcr-Abl)
all cause platelet dysfunction via inhibition of platelet kinases,
while drugs like idelalisib (PI3K, P110δ) inhibit platelet kinases
without increasing bleeding risk. This necessitates strategies to
manage bleeding risk, such as contraindication with antiplatelet
medication or cessation of therapy prior to surgical procedures.
The MEK inhibitors trametinib and cobimetinib were
approved for the treatment of metastatic melanoma in 2013 and
2015, respectively, and target MAPK signalling which is
upregulated in several forms of cancer. Increased rates of hae-
morrhage with MEK inhibitor plus BRAF inhibitor dabrafinib
compared to dabrafinib plus placebo have been recorded in multi-
ple clinical trials evaluating trametinib [1,2] or cobimetinib. In the
majority of cases investigators believed these events to be non-
treatment related, yet one case of intracranial haemorrhage was
attributed to therapy and not tumour cells [3]. Given the ambi-
guity of the role of MEK in platelet function and primary hae-
mostasis, it is not clear if increased rates of bleeding might be
exacerbated by drug-induced platelet dysfunction.
Cobimetinib and trametinib are highly selective, allosteric, non-
ATP competitiveMEK 1 and 2 inhibitors [4,5]. Cobimetinib binds to
phosphorylated MEK (with a 100x greater potency for MEK1 over
MEK2) whilst trametinib binds to non-phosphorylated MEK1 and 2
with similar potencies, though both inhibit downstream ERK signal-
ling. Both cobimetinib and trametinib are used to inhibit
BRAFV600E/K-mediated MEK1 activation, phospho-MEK1 activ-
ity, cellular phosphorylation of ERK, and cellular proliferation. Both
inhibitors display anticancer activity against metastatic melanoma
carrying the BRAF V600E/K mutation. Platelets are known to
express MEK1 and MEK2 [6] and their downstream effectors
ERK1, and ERK2 [7,8] as well as p38MAPK (α and β2 isoforms
and low levels of the γ and δ isoforms) [9] and JNK MAPKs
members, yet the role of this pathway in platelet function has
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remained controversial. In platelets, ERK2 activation is thought to
be mediated by MEK1/2 and seems to be dependent on protein
kinase C (PKC) [10].
Studies using pharmacological MAPK inhibitors have reported
the involvement of MAPK signalling pathways in vWF/GPIb-IX
dependent platelet aggregation [11,12], and the regulation of
platelet functional responses following stimulation by other plate-
let agonists, including regulation of integrin activity [12,13] and
adhesion, spreading and thrombus formation on collagen [14].
Injection with a MEK inhibitor also inhibited thrombus formation
in vivo and caused thrombus destabilisation when administered
following injury of a blood vessel in mouse [15]. However, other
studies have found that pharmacological inhibition of MEK does
not inhibit platelet aggregation [16] or release of secondary med-
iators that support platelet function [17] and have shown that
commonly used MEK inhibitors such as PD0325901 and U0126
inhibit other platelet kinases, possibly explaining their reported
effects on platelet function.
In the present study, we performed thorough pharmacological
characterisation of trametinib and cobimetinib in the context of
platelet signalling and function to determine whether MEK inhi-
bition or indeed off-target inhibition of other platelet signalling
processes by the MEK inhibitors could cause platelet dysfunction
in vitro.
Methods
Materials
Cobimetinib and Trametinib was obtained from SelleckChem
(Stratech, Suffolk, UK). Type I Collagen was obtained from
Nycomed (Munich, Germany) and collagen-related peptide
(CRP-XL) from Professor Richard Farndale (University of
Cambridge, Cambridge, UK). ADP, epinephrine, PMA,
Thrombin and U46619 were from Sigma (Gillingham, UK),
PAR1 activating peptide TRAP-6 (SFLLRN) was from
Bachem (Switzerland). Phospho-PKC substrate antibody,
Phospho-p44/42MAPK (Erk1/2) (Thr202/Tyr204), Phospho-
Akt S473 and Phospho-Akt T308 was from New England
Biolabs (Hitchin, UK). Phospho Src Y418 was from Merck
Millipore, Hertfordshire, UK. β-Actin antibody was from
Abcam (Cambridge, UK). FITC-conjugated anti-fibrinogen
antibody was from Agilent Technologies LDA UK Limited,
(Cheadle, UK) and PE-Cy5 anti- CD62P was from BD
Biosciences (Oxford, UK). Half area 96-well plates were from
Greiner BioOne (Stonehouse, UK) and DiOC6 was from
Thermo Fisher Scientific (Dartford, UK). For antibody catalo-
gue numbers please refer to major resources table in the sup-
plemental material.
Platelet preparation
Blood samples were obtained from healthy, aspirin free, consent-
ing volunteers, using procedures approved by the University of
Reading Research Ethics Committee. Blood was collected into a
syringe containing 3.8% (w/v) sodium citrate and acid citrate
dextrose (ACD) was added prior to preparation of platelet-rich
plasma (PRP). Washed platelets were prepared by first isolating
the PRP following centrifugation at 100 g for 20 minutes at room
temperature, and centrifugation once at 350 g for 20 minutes to
pellet the platelets. Platelets were resuspended at at 4 × 108 cells/
ml in modified Tyrode’s-HEPES buffer, (134 mM NaCl, 0.34 mM
Na2HPO4, 2.9 mM KCl, 12 mM NaHCO3, 20 mM N-2-hydro-
xyethylpiperazine-N′-2ethanesulfonic acid, 5 mM glucose and
1 mM MgCl2, pH 7.3) and kept at 30°C before being used
immediately [18].
Aggregometry
For measurement of plate based aggregation in washed platelets:
half area 96-well plates (Greiner) containing platelet agonists at a
range of concentrations: ADP, CRP-XL, U46619, collagen,
TRAP-6 and PMA and washed platelets (4 x 108/ml) were
(loaded onto plates) and shaken at 1,200rpm for 5 minutes at
37°C using a plate shaker (Quantifoil Instruments) as described
by Lordkipanidzé et al [19] and absorption of 405 nm light
measured using a Multiskan Ascent 354 Microplate Reader
(LabSystems). Traditional light transmission based real time
aggregometry was measured using washed platelets (4 x 108/ml)
under stirring conditions (1200 rpm) at 37°C for 5 minutes in an
AggRAM aggregometer (Helena Biosciences, Europe).
FACS measurement of fibrinogen binding, P-selectin
exposure and Annexin V binding
Measurements of fibrinogen binding, P-selectin exposure and
Annexin V binding were performed using washed platelets pre-
treated with inhibitors as described in figure legends and stimu-
lated with CRP-XL (1 µg/ml) or CRP-XL (1 µg/ml) and TRAP-6
(1 µM) in the presence of FITC-conjugated polyclonal rabbit anti-
fibrinogen antibody, PE-Cy5-conjugated mouse anti CD62P anti-
body or FITC-conjugated Annexin V, and then incubated for
20 minutes in the dark. Platelets were then fixed by addition of
filtered formyl saline (0.2% formaldehyde in 0.15 M NaCl) and
median fluorescence intensities were measured for 5000 events in
the platelet gate (determined by forward and side scatter profiles)
per sample on an Accuri C6 Flow Cytometer (BD Biosciences,
UK) using CFlow Sampler software.
Thrombus formation under flow
Thrombus formation was performed using blood from healthy
donors using microfluidic flow chips (Vena8, Cellix Ltd,
Dublin, Ireland) coated with 100 µg/ml type I collagen and
measured in real time for 9 minutes, at a perfusion shear rate of
1000 s−1 following incubation of blood with cobimetinib, trame-
tinib or vehicle for 10 minutes.
Protein phosphorylation studies, immunoblotting
Washed platelets at 4 × 108 cells/ml were incubated with cobi-
metinib or trametinib at concentrations specified in individual
figures or vehicle for 10 minutes at 37°C prior to addition of
1 µg/ml CRP-XL or 1 µM TRAP-6. Samples were incubated for
90 secs and 60 seconds respectively with stirring at 37°C using an
aggregometer (Helena) prior to addition of reducing Laemmli
sample treatment buffer. Immunoblotting was performed using
standard techniques as described previously [20]. Levels of phos-
phorylated proteins were detected using phospho-specific primary
antibodies and fluorophore conjugated secondary antibodies and
visualised using a Typhoon Trio fluorescence imager and Image
Quant software (GE Healthcare). Band intensities were quantified
and levels of the immunoprecipitated protein were used to control
for protein loading using Image Quant software.
Platelet adhesion
Washed platelets at 2 × 107 cell/ml were exposed to collagen-
(100 µg/ml), fibrinogen- and von-Willebrand factor-coated 96-
well assay plates and allowed to adhere for 45 minutes at 37°C.
Non-adherent platelets were removed by washing in PBS before
fixing with 10% formyl saline for 10 minutes. The wells were
then washed and labelled with DiOC6. Fluorescence images of
adherent platelets were captured with the 20 x objective lens of an
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ImageXpress Nano high content imaging system and counted
using CellReporterXpress software (Molecular Devices,
Winnersh, UK).
Statistical methods
Statistical testing described in figure legends and the results
section were performed using GraphPad Prism Software
(Graphpad, La Jolla, CA). Where data are normalised, this was
done to control for unwanted sources of variation and statistical
analysis was performed prior to normalisation. P ≤ 0.05 was
considered statistically significant. Unless stated otherwise,
values are expressed as mean ±SEM.
Results
MEK inhibitors induce platelet dysfunction only at
suprapharmacological concentrations
To investigate whether MEK inhibitor-induced platelet dysfunc-
tion might contribute to the increased incidence of bleeding
observed during MEK inhibitor therapy, we first investigated
platelet aggregation using both a high-throughput microtitre
plate-based assay (Figure 1a). Washed platelets were treated
with a range of MEK inhibitor concentrations and then stimulated
with 1 µg/ml CRP-XL, 1 µg/ml collagen, 10 µM TRAP-6
(SFLLRN), 1 µM U46619 or 10 µM ADP. Trametinib did not
inhibit platelet aggregation evoked by any of the agonists even at
the highest concentration tested (30 µM). In contrast cobimetinib
inhibited aggregation evoked by all of the agonists, although with
low potency and failed to totally ablate aggregation evoked by any
of the agonists except CRP (log IC50 = −4.9 M ± 0.02). Similar
results were also observed following stimulation by lower con-
centrations of platelet agonists (0.1 and 0.3 µg/ml CRP-XL and
0.1, 1 µM TRAP-6) indicating MEK inhibition does not just occur
at low concentrations of platelet agonists (Supplementary
Figure 1). Further investigation of the effect of the MEK inhibi-
tors on the profile of platelet aggregation using real-time tradi-
tional light transmission aggregometry identified no inhibition of
the kinetics or extent of platelet aggregation to either 1 µg/ml
CRP-XL or 1 µM TRAP-6 by either cobimetinib or trametinib
Figure 1. Only suprapharmacological concentrations of MEK inhibitors cause dysfunctional platelet aggregation and adhesion.Washed human platelets
were pre-treated with increasing concentrations of Cobimetinib (red) or Trametinib (blue) (0.1–100 µM) for 10 minutes prior to a) stimulation with
either i) CRP (1 µg/ml), ii) collagen (1 µg/ml), iii) TRAP-6 (10 µM), iv) U46619 (1 µM) or v) ADP (10 µM) and the extent of platelet aggregation was
monitored after 5 minutes of shaking using an optical light transmission plate based aggregometry assay, and concentration response curves b) and
representative images c) of platelets adhered to i) collagen (10 µg/ml), ii) vWF (10 µg/ml) or iii) fibrinogen (100 µg/ml) coated wells of microtitre
plates for 1 hour at room temperature, data expressed as number of adhered platelets (platelet count). Results are mean + S.E.M. for n ≥ 3, * indicates
p ≤ 0.05 in comparison to vehicle controls.
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even at the highest concentrations tested (10 µM) (Supplementary
Figure 1). The effects of the MEK inhibitors on adhesion of
platelets to collagen, vWF or fibrinogen coated surfaces
(Figure 1b-c) was also determined using a microtitre plate-based
method. We found that both trametinib and cobimetinib were
weak inhibitors of adhesion to collagen and vWF but that cobi-
metinib inhibited adhesion to fibrinogen strongly in some experi-
ments, but only at high concentrations (≥ 3 µM).
The effects of cobimetinib and trametinib on integrin αIIbβ3 activa-
tion and α granule secretionwere determined using flow cytometry to
measure fibrinogen binding and P-selectin exposure, as these pro-
cesses are critical for platelet function (Figure 2). As observed for
aggregation, we found that cobimetinib inhibited CRP-evoked fibri-
nogen binding (logIC50 = −5.2 M ± 0.17) and P-selectin exposure
(logIC50 = −5.2 M ± 0.01) but that trametinib showed no inhibitory
effect (Figure 2a). Similarly, activation by TRAP-6 was inhibited
partially by cobimetinib, although not potently enough to enable
estimation of IC50 values, and was not inhibited by trametinib
(Figure 2b). Cobimetinib was also found to inhibit U46619-evoked
integrin αIIbβ3 activation (logIC50 = −4.9 M ± 0.09) and P-selectin
exposure (logIC50 = −5.2 M ± 0.04) while trametinib only partially
inhibited these responses even at the highest concentration tested
(30 µM) (Figure 2c). Similar to the results seen with U46619, cobi-
metinib inhibited ADP-evoked integrin αIIbβ3 activation
(logIC50 = −5.2 M ± 0.25) and P-selectin exposure
(logIC50 = −5.1 M ± 0.04) while trametinib only partially inhibited
at 30 μM (Figure 2d).
Exposure of phosphatidylserine (PS) is an key step in the
formation of procoagulant platelets which supports the processes
of coagulation that enable stable thrombus formation. The effects
of cobimetinib and trametinib on Annexin V binding were deter-
mined using flow cytometry (Supplementary Figure 2a). We
found that neither cobimetinib or trametinib were capable of
stimulating PS exposure in the absence of platelet stimulation,
indicating neither MEK inhibitor elicits procoagulant platelet
formation or initiates platelet apoptosis. As observed for other
platelet functional responses, we found that cobimetinib inhibited
Annexin binding (logIC50 = −5.1 M ± 0.76) following platelet
stimulation with a combination of CRP-XL (1μg/ml) and TRAP
(10 μM), but that trametinib showed no inhibitory effect
(Supplementary Figure 2b).
The ability of platelets to form stable aggregates under arterial
shear is critical for normal haemostasis. We therefore investigated
the effects of cobimetinib and trametinib in an in vitro assay of
thrombus formation under arterial flow conditions using whole
blood (Figure 3). We found that accumulation of platelets on
collagen coated flow chambers, normalised to maximum vehi-
cle-treated response to compensate for differences between
donors, occurred at a similar rate following treatment with
10 µM cobimetinib or trametinib compared to vehicle-treated
Figure 2. Only suprapharmacological concentrations of MEK inhibitors inhibit integrin αIIbβ3 activation and alpha granule secretion.Washed human
platelets were pre-treated with increasing concentrations of Cobimetinib (red) or Trametinib (blue) (0.1–30 µM) for 10 minutes prior to stimulation
with (a) CRP (1 µg/ml), (b) TRAP-6 (10 µM), (c) U46619 (1 µM) or (d) ADP (10 µM) for 20 minutes before cells were fixed and (i) fibrinogen binding
and (ii) P-selectin exposure were measured by flow cytometry. Results are mean + S.E.M. for n ≥ 3, * indicates p ≤ 0.05 in comparison to vehicle
controls.
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controls (Figure 3a). The morphology of thrombi formed in either
MEK inhibitor-treated whole blood appeared identical to vehicle-
treated control (Figure 3b) and quantitation of non-normalised
platelet deposition onto collagen after 9 minutes was not signifi-
cantly different to vehicle-treated controls following treatment
with either cobimetinib or trametinib (10 μM) (p > 0.05, 1-way
ANOVA with matched pairs and Dunnett’s multiple comparison
test, Figure 3c).
MEK is dispensable for normal platelet function and
signalling
Given the lack of potent antiplatelet effects following treat-
ment of platelets with MEK inhibitors, we investigated plate-
let signalling events to clarify the role of MEK and other
signalling kinases in platelet function. We found that stimula-
tion of platelets with 1 µg/ml CRP or 10 µM TRAP-6 evoked
robust ERK1/2 phosphorylation at threonine 185 and tyrosine
187 (Figure 4) which is mediated by MEK and is required for
ERK1/2 kinase activity [21,22]. Treatment of platelets with
cobimetinib potently inhibited ERK1/2 phosphorylation
evoked by CRP (logIC50 = −9.5 M ± 0.53) and TRAP-6
(logIC50 = −9.5 M ± 0.47) (Figure 4a-b). Similar observa-
tions were also made following treatment with trametinib,
with significant attenuation of ERK1/2 phosphorylation
evoked by CRP (logIC50 = −10.9 M ± 0.43) and TRAP-6
(logIC50 = −9.6 M ± 0.44) (Figure 4a-b).
As we observed cobimetinib and trametinib are both potent
inhibitors of platelet MEK activity (nM) but weak inhibitors of
platelet function (μM), we concluded that inhibition of MEK
activity was unlikely to be the cause of the observed inhibition
of platelet function. We therefore went on to investigate inhibition
of other kinases that are important for platelet function that might
cause platelet dysfunction observed at supraphysiological concen-
trations of cobimetinib (Figure 5).
mTOR and ILK mediate phosphorylation of Akt, a down-
stream effector of PI3K platelet signalling, at S473 and phos-
phorylation of this site was potently inhibited by both
cobimetinib (logIC50 = −8.0 M ± 0.16) and trametinib
(logIC50 = −8.2 M ± 0.28, Figure 5a-d). In contrast, the
PDK1 phosphorylation site on Akt T308 was inhibited by
cobimetinib but not by trametinib, and the inhibition of
T308 observed with cobimetinib was with much lower
potency (logIC50 = −5.4 M ± 0.65) than that observed for
inhibition of Akt S473 (Figure 5b-d). We investigated PKC
activity by measuring total phosphorylation of PKC substrates
and found that cobimetinib inhibited PKC activation with low
potency (logIC50 = −5.3 ± 0.28) and trametinib caused no
inhibition of PKC activity (Figure 5c-d). Cobimetinib also
caused inhibition of PMA induced platelet aggregation
(Figure 5e) and PKC substrate phosphorylation (Figure 5f)
strongly suggesting that cobimetinib may directly inhibit Ser/
Thr kinases such as PKC and Akt and exert off-target effects
on platelet function through this mechanism.
In order to establish the how cobimetinib causes inhibition of
platelet responses, we compared the potencies of the MEK inhi-
bitors on platelet function with their effects on kinase activity
(Figure 6). Although both kinases inhibit MEK and the kinases
that mediate phosphorylation of Akt at S473, both trametinib and
cobimetinib mediated these effects with a potency (IC50 nM) that
is significantly greater than the potency with which they elicit
inhibitory effects on platelet function (IC50 μM)). We therefore
conclude that inhibitory effects on ERK1/2 T185/Y187 and Akt
S473 are not related to the observed inhibitory effects on platelet
function. In contrast, cobimetinib also inhibited PKC substrate
phosphorylation and phosphorylation of Akt T308 with a potency
that was not significantly different from that required to inhibit
platelet function.
Combined BRAF and MEK inhibitors do not impair platelet
function
MEK inhibitors are administered in combination with BRAF inhi-
bitors to improve progression free survival. Although platelets
express BRAF, a role for BRAF in normal platelet function has
not been reported. However, given that cobimetinib and trametinib
are administered with the BRAF inhibitors vemurafenib and dab-
rafenib, respectively, it was important to establish the effects of
these drugs alone and in their therapeutic combinations to deter-
mine whether BRAF inhibitors cause platelet-dysfunction that
could contribute to bleeding events in patients. We found that
vemurafenib inhibited CRP-evoked platelet aggregation
(logIC50 = 4.6 ± 0.61 (M), Figure 7a(i)) but not aggregation
evoked by TRAP-6 (supplementary Figure 3). Dabrafenib did not
inhibit aggregation evoked by CRP (Figure 7a(i)) or TRAP-6
(supplementary Figure 3). Vemurafenib is reported to have off
target effects on the tyrosine kinase Src, which is critical for normal
platelet function. In support of this, phosphorylation of Src at Y418
was reduced in CRP-stimulated platelets following treatment with
vemurafenib at a similar potency (logIC50 = −4.9 ± 0.09 (M)) to
the observed inhibition of platelet function (supplementary
Figure 3. MEK inhibitors do not cause dysfunctional thrombus formation
in whole blood. DiOC6 loaded human whole blood was pre-treated with
vehicle (black), 10 µM cobimetinib (red) or 10 µM trametinib (blue) for
10 minutes, before perfusion through collagen coated (100 µg/ml)
Vena8Biochips at a shear rate of 1000s−1. (a) Real time thrombus forma-
tion was determined for 9 minutes by comparing fluorescence intensity in
the vehicle and treated samples. Maximum fluorescence observed in the
vehicle control was set at 100%. (b) Representative images taken at
9 minutes are shown. (c) Maximum thrombus formation determined by
maximum fluorescence and expressed as arbitrary fluorescence units.
Results are mean ±S.E.M. for n ≥ 3, * indicates p ≤ 0.05 in comparison
to vehicle controls.
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Figure 1). Although vemurafenib reaches therapeutic concentra-
tions of up to 100 µM, it is highly bound by plasma proteins
(approximately 99% plasma bound). In order to establish the effect
of BRAF inhibitors on platelet function, we tested the potency of
the BRAF inhibitors at inhibiting CRP-evoked aggregation of PRP
and found that neither drug caused inhibition of aggregation in PRP
even at 100 µM (Figure 7a(ii)). We tested for potential synergy
between BRAF and MEK inhibitors by titrating the inhibitors
against each other and measuring CRP evoked aggregation
(Figure 7b(i) and b(ii)). We found no enhancement of potency
(IC50) when combining vemurafenib with cobimetinib or dabrafe-
nib with trametinib (non-zero gradient linear regression, p > 0.05,
Figure 7c).
Discussion
The MEK inhibitors cobimetinib and trametinib are currently
used in combination with BRAF inhibitors for treatment of meta-
static melanoma carrying the BRAF V600E/K mutation [4,5].
Increased rates of haemorrhage with cobimetinib or trametinib
plus BRAF inhibitor dabrafinib compared to dabrafinib plus
placebo have been recorded in several clinical trials [1,2].
Whether these events are treatment related is currently unclear
[3]. Platelet dysfunction has been implicated in increased bleed-
ing associated with other kinase inhibitor cancer therapies such as
ibrutinib [18,23–26] and dasatinib [27]. Platelets express several
members of the MAPK signalling cascade including both MEK1
and MEK2 and their downstream effectors ERK1 and ERK2.
However, the role of MEK signalling in the regulation of platelet
function is unclear, as several contradictory reports have been
published [10–13,15–17]. As a result, the role for MEK in the
regulation of platelet function, and the potential for MEK inhibi-
tors such as cobimetinib and trametinib to adversely affect platelet
function have remained ambiguous.
We investigated whether MEK inhibitors caused platelet dys-
function to establish whether this might contribute to increased
risk of haemorrhage observed during therapy with MEK inhibi-
tors. We identified that whilst both MEK inhibitors were highly
potent inhibitors of MEK activity in platelets (Figure 4), cobime-
tinib inhibited important markers of platelet function; aggrega-
tion, adhesion, integrin activation, alpha granule secretion,
phosphatidylserine exposure and thrombus formation, with low
potency and trametinib showed virtually no inhibitory effect at all.
Our findings clearly demonstrate that platelets are able to function
normally under conditions where MEK activity is fully inhibited.
Previous studies have reported a role for MEK signalling in
Figure 4. Cobimetinib and trametinib potently inhibit platelet MEK activity and phosphorylation of MEK substrate ERK1/2. Washed human platelets
were pre-treated with increasing concentrations of cobimetinib or trametinib (0.1 nM-30 µM) for 10 minutes prior to stimulation with (a) CRP (1 µg/
ml) or (b) TRAP-6 (10 μM) under aggregating conditions for 90 and 60 secs respectively before lysis in SDS Laemmli sample buffer, and western
blotting for phosphorylation of ERK at T185/Y187. (i) Levels of total phosphorylation were quantified and expressed as a percentage of vehicle-treated
stimulated controls and actin was used to confirm equal loading. (ii) Representative blots shown. Results are mean and ±S.E.M. for n ≥ 3, * p < 0.05,
** p < 0.01 relative to vehicle-treated controls.
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thromboxane A2 generation downstream of GPIb [11] and the
ADP receptors P2Y1 and P2Y12 [28]. However, we observed no
effect of either MEK inhibitor on adhesion and spreading on
vWF, or thrombus formation under flow, a test which is highly
dependent on both vWF and TxA2 generation in citrated blood.
We also observed no effect that could be attributed to inhibition
of MEK, on aggregation, integrin αIIbβ3 activation or α-granule
secretion evoked by ADP.
It is possible that differences in assay design could underpin
differences between our study and others, but we sought pri-
marily to investigate the physiologically relevant effects of
MEK inhibition on platelet function and were unable to
Figure 5. Inhibition of phosphorylation of the MEK substrate, ERK does not correlate with inhibition of platelet activation markers. Washed human
platelets were pre-treated with increasing concentrations of cobimetinib or trametinib (0.1 nM-30 µM) for 10 minutes prior to stimulation with (a-d)
CRP (1 µg/ml) for 90 seconds and (e) PMA (100 nM) for 10 minutes under aggregating conditions for 90 secs before lysis in SDS Laemmli sample
buffer, and western blotting for phosphorylation of (a) Akt S473, (b) Akt T308 and (c) and (f) total PKC substrates using phospho-site specific
antibodies. Levels of total phosphorylation were quantified and expressed as a percentage of vehicle-treated-stimulated controls and actin was used to
confirm equal loading. (d) and (g) representative blots shown. (e) the extent of platelet aggregation was monitored after 5 minutes of shaking using an
optical light transmission plate based aggregometry assay, and concentration response curves were plotted. Results are mean and ±S.E.M. for n ≥ 3, *
p < 0.05, ** p < 0.01 relative to vehicle-treated controls.
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identify any. A study of the MEK inhibitor U0126 found that
concentrations of U0126 that fully inhibited ERK1/2 phosphor-
ylation did not inhibit aggregation evoked by a range of dif-
ferent agonists, whereas inhibition of aggregation at higher
concentrations was due to activity against targets other than
MEK [16]. Another study using the MEK inhibitor PD 98059
found that inhibition of ERK1/2 activation by MEK did not
alter platelet responses to the physiological agonists collagen
or thrombin [17]. We believe that the disparity between the
concentrations (nM) of cobimetinib required to inhibit MEK
activity and the concentrations (μM) required to inhibit platelet
function are due to off-target effects of the drug. These are
most likely on PKC activity, either directly or through one of
the kinases that activate PKC via phosphorylation of key resi-
dues in their catalytic domain, such as PDK-1 [29]. In support
of this we found that phosphorylation of the PDK-1 substrate
Akt T308 was inhibited by cobimetinib but not trametinib at
supraphysiological concentrations, and we also observed inhi-
bition of PKC substrate phosphorylation and aggregation fol-
lowing stimulation by the PKC activator PMA (Figure 5).
Trametinib has greater selectivity for MEK than cobimetinib
and the only MEK-independent signalling event that we found
to be inhibited by trametinib was phosphorylation of Akt S473,
a PDK-2 and ILK substrate, trametinib otherwise appears to
lack the off-target effects on either platelet function or PKC
activity observed with cobimetinib.
Following oral administration, cobimetinib is reported to
reach a plasma concentration of approximately 18 nM [30]
while trametinib reaches approximately 9.7 nM [31].
Following treatment with similar concentrations of cobimetinib
or trametinib in vitro, whilst ablation of CRP or TRAP-6
evoked phosphorylation of ERK1/2 T185/Y187 was observed,
no alteration in platelet aggregation, integrin activation, alpha
granule secretion or adhesion and spreading on collagen, fibri-
nogen or vWF was detected. Although the concentration-effect
relationship observed in vitro may not directly translate into the
effects observed in vivo. The window between the effects on
platelet function and MEK inhibition was sufficiently large
(approximately 1,000-fold) that acute drug induced platelet
dysfunction during treatment with cobimetinib or trametinib
can effectively be ruled out.
As a strategy to minimise drug resistance, increase cancer
therapy efficacy and overcome the Raf paradox, MEK inhibitors
are administered in combination with BRAF inhibitors and so we
felt it was important to ensure that combination of MEK inhibi-
tors with their corresponding BRAF inhibitors did not synergise
to cause platelet inhibition within the therapeutic range. BRAF is
reported to be expressed in platelets, but a role for BRAF in
platelet function has not previously been reported. We found
that vemurafenib but not dabrafenib inhibited platelet function
to both CRP and TRAP-6 at high but not pharamcologically
relevant inhibitor concentrations, most likely due to off-target
inhibition of Src phosphorylation and activity.
In summary, we found that both MEK inhibitors inhibited
ERK phosphorylation potently, without affecting platelet func-
tion. The high degree of potency and selectivity at nanomolar
concentrations of the inhibitors cobimetinib and trametinib
enabled us to state confidently that phosphorylation of ERK
by MEK is not required for normal platelet aggregation, adhe-
sion, alpha granule secretion or thrombus formation. While
cobimetinib was able to inhibit several functional platelet
responses at high (suprapharmacological) concentrations,
these were found to be due to off-target inhibition of platelet
downstream signalling events including inhibition of both Akt
and PKC activity, likely caused by inhibition of PDK1.
Study of the role of MEK and ERK in platelets has been
highly dependent on pharmacological inhibitors due to the lack
of viability of KOs and lack of nucleated cell models that
would permit use of siRNA or other knockdown techniques.
However, trametinib in particular is highly specific for MEK
over other platelet kinases and therefore might offer the clear-
est answer yet as the importance of MEK and its regulation of
ERK1/2 in platelets. Our findings suggest that ERK is either
able to perform platelet-specific functions in the absence of
MEK activity or that the use of pharmacological inhibitors in
previous studies has led to some misattribution of platelet
signalling roles to MEK-mediated activation of ERK1/2. ERK
signalling is, however, important in the megakaryocyte where
ERK1/2 regulates expression of genes involved in development
and thrombopoeisis [32]. Other transcription factors, such as
members of the nuclear receptor family [33–43], NFƙB, IƙBK
and IKKB [44–47], and STAT3 [48,49] have been found to
Figure 6. MEK activity is dispensable for platelet function.A scatter plot comparing the potencies (log IC50) of cobimetinib and trametinib in platelet
function tests (aggregation, fibrinogen binding and p-selectin exposure) relative to inhibition of different platelet kinases.
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exert non-genomic effects on platelet function; however, it is
possible that the MEK ERK signalling pathway could lead to a
dead end due to the anucleate nature of the platelet.
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concentrations of b (i) cobimetinib or b (ii) trametinib respectively (0.1–30 µM), prior to stimulation by CRP (1 µg/ml) and the extent of platelet
aggregation was monitored after 5 minutes of shaking using an optical light transmission plate based aggregometry assay. (c) comparison of the IC50’s
for vemurafenib and dabrafenib in the presence of different concentrations of cobimetinib or trametinib respectively. Results are mean and ± S.E.M. for
n ≥ 3, * p < 0.05, ** p < 0.01 relative to vehicle-treated controls.
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